bofutrelvir   Click here for help

GtoPdb Ligand ID: 11070

Synonyms: compound 11a [PMID: 32321856] | DC-402234 | DC402234 | FB-2001 | FB2001
PDB Ligand
Compound class: Synthetic organic
Comment: Compound 11a is an inhibitor of SARS-CoV-2 main protease (Mpro) [1]. It interacts with Cys145 of Mpro and it inhibits both protease activity and SARS-CoV-2 infectivity in vitro. Given its low in vivo toxicity and favourable PK profile, 11a is considered to be a valuable lead candidate. Based on commentary in a review by Zhao et al. (2022) [3], compound 11a appears to be the Mpro inhibitor that is being tested in clinical trials as FB2001 (and which is also known as DC402234). The chemical structure of this compound matches that provided for the INN bofutrelvir.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 4
Rotatable bonds 11
Topological polar surface area 120.16
Molecular weight 452.24
XLogP 3.7
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES O=C[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@@H](NC(=O)c1cc2c([nH]1)cccc2)CC1CCCCC1
Isomeric SMILES O=C[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@@H](NC(=O)c1cc2c([nH]1)cccc2)CC1CCCCC1
InChI InChI=1S/C25H32N4O4/c30-15-19(13-18-10-11-26-23(18)31)27-24(32)21(12-16-6-2-1-3-7-16)29-25(33)22-14-17-8-4-5-9-20(17)28-22/h4-5,8-9,14-16,18-19,21,28H,1-3,6-7,10-13H2,(H,26,31)(H,27,32)(H,29,33)/t18-,19-,21-/m0/s1
InChI Key HPKJGHVHQWJOOT-ZJOUEHCJSA-N
No information available.
Summary of Clinical Use Click here for help
Bofutrelvir (FB2001) has progressed to clinical evaluation for potential to treat SARS-CoV-2 infection (COVID-19).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04766931 The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection Phase 1 Interventional Frontier Biotechnologies Inc.
NCT05415241 Exploratory Study of Aerosol Inhalation of FB2001 for Post-exposure Prophylaxis of COVID-19 Close Contacts Phase 1/Phase 2 Interventional Ruijin Hospital
NCT05445934 Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study) Phase 2/Phase 3 Interventional Frontier Biotechnologies Inc.